Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Pannexin-3 (PANX3)** is a member of the pannexin family of large-pore, ATP-permeable channels that structurally resemble innexins (invertebrate gap junction proteins) but are distinct from connexins. PANX3 is predominantly expressed in hard tissues such as cartilage, bone, and skin, where it acts as an essential regulator of cellular differentiation and tissue development, particularly in osteoblasts, chondrocytes, and odontoblasts[1][2][4][7][8][9]. PANX3 channels function as ER Ca^{2+} channels, hemichannels for ATP release, and intercellular gap junctions, thereby controlling intracellular Ca^{2+} signaling, extracellular ATP-mediated signaling, and coordination of cell fate transitions. Genetic deletion leads to significant skeletal formation defects, indicating its indispensability for healthy bone and cartilage development. Targeted modulation of PANX3 is a topic of ongoing investigation in skeletal and regenerative medicine, but it has no clinically approved therapeutics or inhibitors at present[1][2][7][9].
Not applicable for any approved or clinical drugs (no specific modulators or inhibitors are currently documented for therapeutic use).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pannexin-3 (PANX3).